Thomas Grogan

Q: What Schools Are Affiliated With Thomas Grogan

Thomas Grogan is affiliated with the following schools: George Washington University, Ohio State University, University of Arizona, Louisiana State University, Stanford University, University of Colorado, Oregon Health & Science University, Johns Hopkins University, University of Virginia, Arizona Board of Regents, Harvard University

Thomas Grogan's AcademicInfluence.com Rankings

Thomas Grogan

Philosophy

#9780

World Rank

#13388

Historical Rank

#1782

USA Rank

Logic

#6735

World Rank

#8282

Historical Rank

#954

USA Rank

philosophy Degrees

Download Badge

Philosophy

Thomas Grogan's Degrees

Doctorate Medicine Harvard University
PhD Pathology Johns Hopkins University

Why Is Thomas Grogan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Thomas Grogan is an American professor, pathologist and founder of Ventana Medical Systems, Inc. He currently holds the positions of Professor of Pathology at the University of Arizona College of Medicine and Chief Scientific Officer at Ventana.

(See a Problem?)

Thomas Grogan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. (2002) (2370)
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. (1993) (2215)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. (2004) (1410)
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma (2003) (1074)
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. (1998) (975)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. (2003) (948)
Molecular diagnosis of Burkitt's lymphoma. (2006) (871)
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (2012) (844)
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. (1999) (567)
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. (1989) (561)
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. (1996) (432)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. (2005) (400)
P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. (1991) (393)
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. (2001) (368)
P-glycoprotein expression and function in circulating blood cells from normal volunteers. (1994) (365)
A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. (1995) (364)
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. (2004) (362)
Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. (2001) (347)
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. (2004) (317)
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. (2004) (284)
Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. (1991) (269)
Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. (1994) (259)
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. (1996) (250)
Utility of fine-needle aspiration as a diagnostic technique in lymphoma. (2004) (248)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. (2007) (243)
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. (1992) (240)
Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) (1990) (237)
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. (2006) (231)
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. (2002) (231)
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. (1991) (229)
Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. (1993) (222)
Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. (1989) (218)
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. (2000) (192)
Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). (1990) (187)
Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. (2007) (183)
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. (1994) (171)
Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypes. (1985) (171)
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 (1988) (167)
Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas (1999) (163)
Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. (1997) (161)
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. (2008) (156)
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression (2011) (155)
A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study (1995) (153)
CALLA-positive myeloma: an aggressive subtype with poor survival. (1985) (151)
The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. (1988) (144)
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. (1994) (143)
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. (2001) (138)
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. (1989) (136)
Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas (2003) (133)
Development and characterization of a melphalan-resistant human multiple myeloma cell line. (1991) (131)
P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. (1997) (130)
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. (1993) (127)
The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study (2005) (123)
Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation (1989) (122)
Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder (2008) (120)
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. (1994) (115)
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. (2006) (110)
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. (2001) (108)
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH) (2008) (106)
Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features (1987) (105)
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. (2005) (102)
HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. (1988) (101)
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. (1988) (101)
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy (1993) (99)
Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. (1997) (99)
Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. (1990) (98)
Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. (1999) (95)
A comparative study of Burkitt's and non‐Burkitt's “undifferentiated” malignant lymphoma: Immunologic, cytochemical, ultrastructural, cytologic, histopathologic, clinical and cell culture features (1982) (95)
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures (2005) (93)
Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma: Comparison With FISH and Assessment of Interobserver Reproducibility (2010) (91)
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. (2001) (90)
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma (2010) (90)
Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. (1982) (87)
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). (2003) (84)
Myelomonocytic Antigen Positive Multiple Myeloma (1989) (83)
Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. (1993) (81)
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. (2001) (79)
The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. (1989) (76)
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. (2005) (75)
Cell Cycle Alterations in the Blastoid Variant of Mantle Cell Lymphoma (MCL-BV) as Detected by Gene Expression Profiling of Mantle Cell Lymphoma (MCL) and MCL-BV (2003) (73)
Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. (1999) (70)
Lethal midline granuloma with a novel T‐Cell phenotype as found in peripheral T‐Cell lymphoma (1987) (69)
Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas (2013) (69)
The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. (2010) (67)
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. (2000) (67)
A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility (2007) (65)
Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). (1996) (63)
Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. (1990) (63)
Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.1 (2003) (62)
NCAM (CD56)-positive malignant lymphoma. (1993) (60)
Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. (1990) (60)
Establishment of two new myeloma cell lines from bilateral pleural effusions: evidence for sequential in vivo clonal change. (1985) (58)
Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin. (1997) (58)
Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. (1990) (58)
Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinomas (2011) (56)
Signet-ring cell lymphoma of T-cell origin. An immunocytochemical and ultrastructural study relating giant vacuole formation to cytoplasmic sequestration of surface membrane. (1985) (55)
The assessment of HER2 status in breast cancer: the past, the present, and the future (2016) (55)
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma (2007) (54)
Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. (1993) (54)
Long-term engraftment of fresh human myeloma cells in SCID mice. (1992) (53)
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. (2012) (52)
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections (2012) (51)
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. (2003) (50)
Follicular lymphomas: do histologic subtypes predict outcome? (1997) (48)
Analytical Validation and Interobserver Reproducibility of EnzMet GenePro: A Second-Generation Bright-Field Metallography Assay for Concomitant Detection of HER2 Gene Status and Protein Expression in Invasive Carcinoma of the Breast (2005) (46)
The immunoarchitecture of cutaneous pseudolymphoma. (1985) (45)
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer (2014) (45)
Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms (1990) (45)
An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas. (1987) (44)
The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. (1988) (43)
Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. (2006) (43)
Immunophenotypes in "well-differentiated" lymphoproliferative disorders, with emphasis on small lymphocytic lymphoma. (1986) (43)
Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. (1987) (40)
An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. (1993) (39)
An ultrastructural morphometric and immunohistochemical analysis of cutaneous lymphomas and benign lymphocytic infiltrates of skin. Useful criteria for diagnosis. (1986) (37)
Graft-vs-host reaction. (1977) (36)
New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay (2013) (35)
Post-transplantation T cell lymphoblastic lymphoma. (1987) (33)
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. (2001) (33)
Metallographic in situ hybridization. (2007) (33)
Myelomonocytic antigen positive multiple myeloma. (1989) (32)
BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. (2014) (32)
Immunologic complexity of lymphoblastic lymphoma. (1986) (32)
Azathioprine-induced pure red blood cell aplasia. (1978) (32)
BRAF V600E mutation‐specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia (2013) (31)
Human gene therapy for melanoma: CT-guided interstitial injection. (1997) (30)
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups (2013) (30)
Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsies. (1996) (30)
Myelomonocytic myeloma cell line (LB 84-1). (1989) (30)
T-cell antigen-positive multiple myeloma. (1990) (29)
Immunoarchitecture of the human spleen. (1983) (29)
Recombinant Interferon-γ Stimulates the Production of Human Tumor Necrosis Factor In Vitro (1987) (29)
Novel bright field molecular morphology methods for detection of HER2 gene amplification (2004) (27)
Automation of Manual Components and Image Quantification of Direct Dual Label Fluorescence In Situ Hybridization (FISH) for HER2 Gene Amplification: A Feasibility Study (2006) (27)
Altered expression of P‐glycoprotein and cellular adhesion molecules on human multi‐drug‐resistant tumor cells does not affect their susceptibility to NK‐ and LAK‐mediated cytotoxicity (1991) (27)
Application of Automated mRNA In Situ Hybridization for Formalin-fixed, Paraffin-embedded Mouse Skin Sections: Effects of Heat and Enzyme Pretreatment on mRNA Signal Detection (2003) (27)
A comprehensive immunotopographic map of human thymus. (1988) (26)
Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma. (2013) (26)
Identification of two major B cell forms of nodular mixed lymphoma. (1984) (26)
Cutaneous myiasis. Immunohistologic and ultrastructural morphometric features of a human botfly lesion. (1987) (26)
Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? (1991) (25)
Lennert's lymphoma: A clinicopathologic study with emphasis on phenotype and its relationship to survival (1988) (25)
Diagnosis and reversal of multidrug resistance in paediatric cancers. (1996) (25)
Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. (1985) (24)
Immunohistochemistry of Colorectal Cancer Biomarker Phosphorylation Requires Controlled Tissue Fixation (2014) (24)
Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. (2000) (24)
The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. (1999) (23)
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas (2010) (23)
Expression of type IV collagenase correlates with the invasion of human lymphoblastoid cell lines and pathogenesis in SCID mice. (1992) (23)
Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models. (2010) (21)
Insulin-like growth factor-1 receptor protein expression and gene copy number alterations in non-small cell lung carcinomas. (2013) (21)
Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas (2014) (20)
Clonal ambiguity of human immunodeficiency virus-associated lymphomas. Similarity to posttransplant lymphomas. (1988) (20)
In situ hybridization in the pathology laboratory: General principles, automation, and emerging research applications for tissue-based studies of gene expression (2004) (20)
Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. (1995) (20)
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. (2005) (19)
Immunophenotyping in the management of gastric lymphoma. (1991) (18)
Mantle zone lymphoma with central nervous system involvement (1986) (18)
Graft-versus-host reaction (GVHR). A case report suggesting GVHR occurred as a result of maternofetal cell transfer. (1975) (18)
Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. (1996) (17)
Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. (1992) (17)
Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features. (2003) (17)
Liver biopsy immunotyping to characterize lymphoid malignancies (1986) (17)
Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype (1996) (17)
Further delineation of the immunoarchitecture of the human spleen. (1984) (17)
Terminal lymphoblastic transformation in polycythemia vera. (1986) (17)
Cytolytic (TIA-1+) tumor infiltrating lymphocytes in B cell non-Hodgkin's lymphomas. SWOG Central Repository Members. (1993) (16)
Comparison of proliferating cell nuclear antigen versus the more standard measures of rectal mucosal proliferation rates in subjects with a history of colorectal cancer and normal age-matched controls. (1995) (16)
Immunobiologic correlates of prognosis in lymphoma. (1993) (16)
Phagocytic, lambda light chain, plasma cell myeloma. (1983) (16)
Loss of B 7 . 2 ( CD 86 ) and Intracellular Adhesion Molecule 1 ( CD 54 ) Expression Is Associated with Decreased Tumor-infiltrating T Lymphocytes in Diffuse B-cell Large-cell Lymphoma 1 (2000) (15)
Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy. (1993) (15)
Automated immunohistochemical analysis. (1992) (15)
Nuclear Contour Irregularity Correlates with Leu‐9, Leu‐8− Cells in Benign Lymphoid Infiltrates of Skin: An Ultrastructural Morphometric and Quantitative Immunophenotypic Analysis Suggesting the Normal T‐Cell Counterpart to the Malignant Mycosis Fungoides/Sézary Cell (1988) (14)
Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800). (2004) (14)
Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency. (1992) (14)
Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL). (2006) (14)
A Southwest Oncology Group perspective on the Revised European-American Lymphoma classification. (1997) (14)
Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2. (2009) (13)
Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. (2012) (13)
BCL 2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma (2016) (13)
Changing patterns of Hodgkin's disease at autopsy: a 25-year experience at the National Cancer Institute, 1953--1978. (1982) (13)
Society for Hematopathology Program (1996) (12)
Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work). (2004) (12)
Expression of Vascular Endothelial Growth Factor and Its Receptors in Hematopoietic Malignancies 1 (1999) (12)
New REAL clinical entities. (1998) (11)
Directed indices for exploring gene expression data (2003) (11)
Burkitt's-like lymphoma of T-cell type. (1988) (11)
An Update on “Special Stain” Histochemistry with Emphasis on Automation (2000) (11)
New biologic markers in non-Hodgkin's lymphomas. (1991) (10)
An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. (2005) (10)
The expression of common acute lymphoblastic leukemia antigen by bile canaliculi. (1985) (10)
A unique malignant T‐cell lymphoproliferative disorder with neutropenia simulating hairy cell leukemia (1985) (10)
Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype. (1991) (10)
Variable Expression of B-cell Transcription Factors in Reactive Immunoblastic Proliferations: A Potential Mimic of Classical Hodgkin Lymphoma (2014) (9)
Recombinant interferon-gamma stimulates the production of human tumor necrosis factor in vitro. (1987) (9)
Immunologic approaches to the classification of non-Hodgkin's lymphomas. (1988) (9)
Reduction of murine cutaneous UVB-induced tumor-infiltrating T lymphocytes by dietary canthaxanthin. (1991) (9)
The role of P-glycoprotein in drug-resistant hematologic malignancies. (1991) (8)
A multidisciplinary approach to the diagnosis of cutaneous T-cell lymphomas. (1992) (7)
Differentiation of chronic lymphocytic leukemia from other "well to intermediate differentiated" lymphoproliferative disorders by the mouse rosette assay. (1986) (7)
The phenomenon of multidrug resistance in non-Hodgkin's lymphoma. (1996) (7)
Southwest Oncology Group clinical trials of chemosensitizers in non-Hodgkinʼs lymphomas: 166 (1994) (7)
Standardization of a single-cell assay for sensitive detection of multidrug resistance protein expression in normal and malignant cells in archival clinical samples. (1997) (7)
High-Resolution Immunophenotyping of Subcellular Compartments in Tissue Microarrays by Enzyme Metallography (2005) (7)
The specificity of interphase FISH translocation probes in formalin fixed paraffin embedded tissue sections is readily assessed using automated staining and scoring of tissue microarrays constructed from murine xenografts (2007) (6)
Lymphomas of the mediastinum. (1991) (6)
Ultrastructural morphometry distinguishes Burkitt's-like lymphomas from neuroendocrine neoplasms: useful criteria applied to the evaluation of a poorly differentiated neuroendocrine neoplasm of the nasal cavity masquerading as Burkitt's-like lymphoma. (1989) (6)
Pseudonodular T cell lymphoblastic lymphoma. (1984) (5)
Allelic loss during progression of follicular lymphoma. (2004) (5)
Quinidine-induced reactive lymphadenopathy. (1987) (5)
Chronic myelomonocytic leukemia terminating as malignant histiocytosis. (1987) (4)
Immunohistochemistry in leukemias and lymphomas. (2001) (4)
Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. (2004) (4)
Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma Lymphoma/Leukemia Molecular Profiling (2007) (4)
Immunoarchitecture of the regenerating rat spleen: effects of partial splenectomy and heterotopic autotransplantation. (1986) (4)
Childhood florid follicular hyperplasia with immunoglobulin light‐chain restriction in the gastrointestinal tract (2014) (3)
An in vivo model of chemosensitization of multidrug resistant human myeloma cell line in SCID mice: 35 (1994) (3)
Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. (2005) (3)
Philadelphia‐chromosome‐negative chronic myelogenous leukemia with lymphoid stem cell blastic transformation (1985) (3)
Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. (2012) (3)
Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically—defined cell populations for gated genotyping (2007) (3)
Immunotopography of splenic lymphoma of small cleaved B-cell type. (1985) (3)
Optimization of P-glycoprotein detection in formalin fixed paraffin embedded tissues utilizing antigen retrieval methods: 23 (1994) (2)
The addition of cyclosporin A (CsA) results in markedly elevated tissue levels of doxorubicin (DOX) in the SCID mouse: 49 (1994) (2)
Development of automated brightfield HER2 and chromosome 17 centromere (CEN17) double in situ hybridization application for breast carcinomas and its performance comparison to manual HER2 fluorescence in situ hybridization (FISH) (2008) (2)
Patients with localized non-Hodgkin's lymphomas provide opportunities for future research. (1991) (2)
Chest radiographic abnormalities in Lennert's lymphoma (1988) (2)
Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. (1995) (2)
In Situ Hybridization (2010) (2)
Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project (2005) (2)
Determination of T cell monoclonality in non-Hodgkin's lymphoma by frozen section immunohistology. The SWOG Central Repository Members. (1992) (2)
The Presence of bcl‐1 and bcl‐2 Gene Rearrangements in Diffuse Small Cleaved‐Cell Lymphoma: A Disease with Diverse Molecular and Immunophenotypic Findings (1994) (2)
Immunophenotyping to detect and characterize acute lymphocytic leukemia in testicular biopsies. (1989) (2)
Invasive breast cancer clinical outcome is predicted by a novel bright-field assay for the simultaneous detection of HER2 gene amplification and protein expression (SILVERFISH). (2004) (1)
Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeatedin vitro sensitization (1991) (1)
Bright-field in situ hybridization methods to discover gene amplifications and rearrangements in clinical samples. (2013) (1)
Pseudo Pelger-Huët anomaly in myelodysplastic syndrome : hyposegmented or apoptotic neutrophil ? (2001) (1)
Gene Expression Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). (2004) (1)
A Highly Sensitive Immunohistochemical Assay to Detect Braf V600E Mutations in Patients with Colorectal Cancer (2012) (1)
Immunotyping malignant lymphomas. A boon to diagnosis. (1986) (1)
Development of RiboMap^ System for Automated mRNA In Situ Hybridization Applications Using Ventana Discovery^ Slide-Processing System(THE SIXTH JAPAN-CHINA JOINT SEMINAR ON HISTOCHEMISTRY AND CYTOCHEMISTRY) (2002) (1)
Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP (2010) (1)
New classification of low-grade lymphoma. (1996) (1)
Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line. (2006) (1)
Does nodal marginal zone lymphoma exist (1999) (1)
P1-07 Automated Colormetric Tyramide Signal Amplification In Situ Hybridization (TISH) Detection of Single HER-2/neu Oncogene Copies (2002) (1)
Philadelphia‐chromosome‐negative chronic myelogenous leukemia with lymphoid stem cell blastic transformation (1986) (1)
Generation of cytotoxic effector cells against human melanoma (1995) (1)
High Throughput Morphological Gene Expression Studies Using Automated mRNA In Situ Hybridization Applications and Tissue Microarrays for Post-Genomic and Clinical Research (2004) (1)
Immunologic and cytochemical characterization of lymphoreticular malignancies. (1981) (0)
Measuring Lymphocytes-Reply (1987) (0)
P1-06 Development of Automated In Situ Hybridization Applications using Oligoprobes and Tyramide Signal Amplification on the Ventana Discovery^ Slide Processor (2002) (0)
The INFORM HER2 Dual ISH assay compared with FISH to determine HER2 gene status in invasive breast carcinoma. (2011) (0)
A multi-institutional evaluation of lymphoma classification (1999) (0)
Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma. (2004) (0)
Improved biological reaction platform. (1991) (0)
David York Mason (1941-2008). Antibody wizard and a founder of modern hemopathology (2008) (0)
In Reply [2] (2005) (0)
Abstract 2218: Integrated diagnostic methods for detection of multiple gene rearrangements in prostate cancer tissue specimens (2011) (0)
Simultaneous Detection and Quantitation of Multiple Antigen Expression in Tissue by Fluorescence Microscopy and Hyper-spectral Imaging (132.4) (2007) (0)
PP44 Development of a quantitative scoring algorithm for a Dual-Hapten, Dual-Color ISH assay (DDISH) to determine HER2 gene status (2009) (0)
The Low‐Grade B‐Cell Lymphoma Polyglot: Is It a Step Forward or Backward? (1995) (0)
To the editor : Misleading information about ALIP and VEGF in myelodysplasia (0)
Development and Characterization of a Melphalan-resistant Human Multiple Myeloma Cell Line1'2 (2006) (0)
P35-M Quantitative Measurement of Gene Expression from Formalin-Fixed Tissue Providing Identical Results as Fresh Tissue: Biomarker Validation using Clinical Samples (2007) (0)
Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies (1994) (0)
Gene expression profiling in laser microdissected normal follicular mantles, mantle cell lymphoma , and blastic variant of mantle cell lymphoma (2002) (0)
Society for Hematopathology: Identifying and Understanding Histiocytic and Dendritic Cell Neoplasms Sunday, March 26, 2000, 1:30 p.m. (2000) (0)
WS3-3 Autoamtion of Slide-based Molecular Assays : (2002) (0)
comments) rare variant with a propensity for unusual sites of involvement (see Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a (2011) (0)
Hematologic investigations: Morphologic and phenotypic features of myeloma marrow diagnosis (2004) (0)
Fine needle aspiration is a feasible and accurate technique in the diagnosis of lymphoma. Authors' reply (2005) (0)
Multiplexed diagnostic biomarker detection and analysis platform for Qdots™ in FFPE samples (2006) (0)
multiple myeloma patients Maintenance therapy with alternate-day prednisone improves survival in (2013) (0)
P5-11-10: Reproducibility and Robustness of the FDA Approved INFORM HER2 Dual ISH DNA Probe Cocktail Assay. (2011) (0)
and kinetic features immunochemical, immunophenotypic, genotypic, cytologic, cell culture, Delineation of a novel pre-B cell component in plasma cell myeloma: (2011) (0)
Morphologie, immunologie and genetic features of Burkitt’s and Burkitt-like lymphomas (1999) (0)
576 Utility of new brightfield dual-color in situ hybridization (BDISH) method for evaluating HER2 gene status of breast cancer patients (2010) (0)
Expression of Na + K + -ATPase in displastia and cervical cancer. (2006) (0)
progenitor formation in myelodysplastic syndromes abnormal localized immature myeloid precursors and leukemia Vascular endothelial cell growth factor is an autocrine promoter of (2013) (0)
Chasing the Invisible: A Doctor's Quest to Abolish the Last Unseen Cancer Cell (2019) (0)
High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. (2004) (0)
527 INTEGRATED DIAGNOSTIC METHODS FOR DETECTION OF MULTIPLE GENE REARRANGEMENTS IN PROSTATE CANCER TISSUE SPECIMENS (2011) (0)
A Philosophical Perspective: The Biologic Principles Underlying Poor Prognosis and Therapy Failure (1996) (0)
Non-Hodgkin's Lymphomas and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) (2013) (0)
Toxicity of Blastomyces dermatitidis (1971) (0)
P-Glycoproteins in Tumors (1995) (0)
Staging laparotomy for Hodgkin's disease. (1983) (0)
survival in mantle cell lymphoma mRNAs that are associated with increased proliferation rate and shorter Point mutations and genomic deletions in Cyclin D1 create stable truncated (2013) (0)
The phenomenon of multi drug resistance in non-Hodgkin ' s lymphoma (0)
Simultaneous Detection and Quantitation of Multiple Antigen Expression in Tissue by Fluorescence Microscopy and Hyper-spectral Imaging (2007) (0)
Combination o f F ludarabine a nd M itoxantrone i n U ntreated Stages I II a nd I V L ow-Grade L ymphoma: S 9501 (2003) (0)
Detection of the BRAFV600E protein in human colon carcinomas by a mutation-specific antibody. (2013) (0)
Automatic biological reactor (1991) (0)
Abstract P4-07-07: Evaluating Rad51/geminin protein expression as an indicator of homologous recombination deficiency in breast cancer models (2016) (0)
Abstract 1769: Loss of major histocompatibility class II expression in diffuse large B-cell lymphoma may be related to stage of B-cell differentiation (2010) (0)
P-Glycoprotein Chemotherapy despite Cyclosporine for Reversal of Retinoblastoma Correlates with the Rare Failure of Multidrug Resistance Protein ( MRP ) Expression in Updated Version (2006) (0)
A method for identifying behandlingsresponderende non-small cell lung cancer using anaplastic lymfomkinase (alk) as a marker (2013) (0)
Development and Characterization of a Melphalan-resistant Human Multiple Myeloma Cell Line 1 ' 2 (2006) (0)
GENE THERAPY OF MALIGNANT MELANOMA(MM) BY THE DIRECT INTRATUMORAL INJECTION OF THE HLA-B7 GENE IN A CATIONIC LIPID VECTOR (1995) (0)
Concomitant delineation of HER2 gene amplification and protein expression status using a two-color bright field immunogenotypic assay (SISHPro HER2) (2008) (0)

This paper list is powered by the following services:

Other Resources About Thomas Grogan

en.wikipedia.org

What Schools Are Affiliated With Thomas Grogan?

Thomas Grogan is affiliated with the following schools:

Thomas Grogan's Academic­Influence.com Rankings